| 15 0 (0%) | 01-19 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 17.52 | 1-year : | 20.46 |
| Resists | First : | 15 | Second : | 17.52 |
| Pivot price | 14.96  |
|||
| Supports | First : | 14.93 | Second : | 14.89 |
| MAs | MA(5) : | 14.99 |
MA(20) : | 14.95 |
| MA(100) : | 12.62 |
MA(250) : | 8.24 |
|
| MACD | MACD : | 0  |
Signal : | 0 |
| %K %D | K(14,3) : | 100 |
D(3) : | 95.8 |
| RSI | RSI(14): 73.1 | |||
| 52-week | High : | 15 | Low : | 3.05 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ AVEO ] has closed below upper band by 10.9%. Bollinger Bands are 94.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 50 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 15.01 - 15.09 | 15.09 - 15.15 |
| Low: | 14.82 - 14.91 | 14.91 - 14.98 |
| Close: | 14.87 - 15 | 15 - 15.12 |
AVEO Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients. It markets its lead candidate, FOTIVDA, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC); and tivozanib for the treatment of RCC, HCC, immunologically cold tumors, and CCA. The company has also completed a Phase II clinical trial of tivozanib in combination with Opdivo (nivolumab) for the treatment of RCC. In addition, it is developing Ficlatuzumab, a potent humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets hepatocyte growth factor that is in a Phase II clinical trial for the treatment of squamous cell carcinoma of the head and neck, pancreatic cancer, and acute myeloid leukemia; AV-203, a potent humanized IgG1 monoclonal antibody, which completed Phase I clinical trial for treating human ErbB3; and AV-380, a potent humanized IgG1 inhibitory monoclonal antibody that is in a Phase I clinical trial for the treatment or prevention of cachexia. The company's preclinical stage product includes AV-353 that targets the Notch 3 pathway. AVEO Pharmaceuticals, Inc. has collaboration agreements with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. Vincent's Hospital Sydney Limited; Biogen Idec International GmbH; Kyowa Kirin Co., Ltd.; and AstraZeneca PLC. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts.
Mon, 22 Apr 2024
Will AVEO (AVEO) Surprise Estimates in Q4 Earnings Again? - Yahoo Movies UK
Thu, 18 Apr 2024
Increased Earnings Estimates Seen for AVEO Pharmaceuticals (AVEO): Can It Move Higher? - Yahoo Movies UK
Thu, 28 Mar 2024
CORRECTION – AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory ... - GlobeNewswire
Thu, 30 Nov 2023
AVEO Oncology, an LG Chem company, Earns Spot on Boston Globe's 2023 Top Places to Work List for Second ... - PR Newswire
Fri, 26 May 2023
Acquisition and Investment Spur AVEO Oncology to New Heights - Pharmaceutical Executive
Wed, 08 Mar 2023
LG Chem's New US Acquisition AVEO Oncology Sets Sights On Being Global Top 20 Innovative Oncology Company - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 35 (M) |
| Shares Float | 34 (M) |
| Held by Insiders | 0.1 (%) |
| Held by Institutions | 34.4 (%) |
| Shares Short | 817 (K) |
| Shares Short P.Month | 969 (K) |
| EPS | -1.21 |
| EPS Est Next Qtrly | -0.1 |
| EPS Est This Year | -0.56 |
| EPS Est Next Year | -0.42 |
| Book Value (p.s.) | 0.82 |
| Profit Margin | -30.8 % |
| Operating Margin | -26 % |
| Return on Assets (ttm) | -14.6 % |
| Return on Equity (ttm) | -72.6 % |
| Qtrly Rev. Growth | 100.6 % |
| Gross Profit (p.s.) | 0.32 |
| Sales Per Share | 2.71 |
| EBITDA (p.s.) | -0.71 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -23 (M) |
| Levered Free Cash Flow | -13 (M) |
| PE Ratio | -12.5 |
| PEG Ratio | 0 |
| Price to Book value | 18.07 |
| Price to Sales | 5.52 |
| Price to Cash Flow | -23.01 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | 2020-02-19 |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|